| Drug Name: | Pergolide (66104-22-1) |
|---|---|
| PubChem ID: | 47811 |
| SMILES: | CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC |
| InchiKey: | YEHCICAEULNIGD-MZMPZRCHSA-N |
| Therapeutic Category: | Dopamine Agents, Dopamine Agonists, Neurotransmitter Agents |
| Molecular Weight (dalton) | : | 314.498 |
| LogP | : | 4.2711 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 2 |
| Hydrogen Bond Donor Count | : | 1 |
| Total Polar Surface Area | : | 19.03 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Levodopa (59-92-7) | Confusion | Additive | Additive dopaminergic effects would be expected. The serotonin syndrome is thought to occur because of increased stimulation of the 5-HT receptors in the brainstem and spinal cord | Clinico-pathologic correlation of liver damage in patients treated with 6-mercaptopurine and adriamycin |
| Levodopa (59-92-7) | Dyskinesia | Additive | Additive dopaminergic effects would be expected. The serotonin syndrome is thought to occur because of increased stimulation of the 5-HT receptors in the brainstem and spinal cord | Increased Incidence of Levodopa Therapy Following Metoclopramide Use |
| Levodopa (59-92-7) | Hallucinations | Additive | Additive dopaminergic effects would be expected. The serotonin syndrome is thought to occur because of increased stimulation of the 5-HT receptors in the brainstem and spinal cord | Clinical pharmacokinetics of 3-day continuous infusion cisplatin and daily bolus 5-Fluorouracil |
| Lisinopril (83915-83-7) | Hypotension | Antagonistic | All dopamine agonists causes hypotensive reactions during the first few days of treatment | Pergolide-induced hypotension |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category